Home › Funds › Bain Capital Life Sciences Investors, LLC › COAG

Bain Capital Life Sciences Investors, LLC position in COAG

HEMAB THERAPEUTICS HLDGS INC · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 1,650,000 shares of COAG (HEMAB THERAPEUTICS HLDGS INC) in its Q3 2026 13F filing — a position valued at US$50.9M, representing 3.50% of its reported portfolio and ranking #11 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)1.65M sh
Reported value held$50.89M
Portfolio Weight3.50%
First reportedQ2 2026
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's COAG position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in COAG in Q2 2026 at 1,650,000 shares (US$60.6M). Across 2 filings, Bain Capital Life Sciences Investors, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,650,000 shares valued at US$50.9M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 1.65M $60.60M New
Q3 2026 1.65M $50.89M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About COAG and 13F data

COAG (HEMAB THERAPEUTICS HLDGS INC) is a Health Care company. 85 other funds we track also report a position in COAG — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$286.8M), Novo Holdings A/S (US$153.6M), Deep Track Capital, LP (US$110.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding COAG

All COAG fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held COAG?

Bain Capital Life Sciences Investors, LLC has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Bain Capital Life Sciences Investors, LLC's current position in COAG?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 1.65M shares of COAG (HEMAB THERAPEUTICS HLDGS INC), valued at $50.89M, representing 3.50% of its reported portfolio and ranking #11.

Has Bain Capital Life Sciences Investors, LLC been buying or selling COAG?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in COAG.

Which other funds hold COAG?

Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Deep Track Capital, LP, among 85 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.